EU Supporting Small Companies
Graz - With Euro2.5 million for the project PONT - “Parallel Optimization of New Technologies for Post-Genomics Drug Discovery” the European Union is supporting post-genomics drug discovery. It is a part of the European Union's 6th Research Programm (FP6). PONT should optimize technologies throughout the drug discovery pipeline for parallel, rather than sequential application in order to maximize efficiency in development of new oncology genomics targets.
Four biotech-companies and two academic partners are involved: Oridis Biomed GmbH (Graz); PSF Biotech AG (Berlin); Nascacell IP GmbH (Munich); Tripos Receptor Research Ltd. (Bude, UK); The Institute of Pathology, Medical University of Graz; and the Institute of Crystallo-graphy, Free University of Berlin.